Oramed Pharmaceuticals
ORMP
19 hedge funds and large institutions have $855K invested in Oramed Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
27% more funds holding
Funds holding: 15 → 19 (+4)
55% less capital invested
Capital invested by funds: $1.91M → $855K (-$1.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$126K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$69K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$32.3K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$31.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$24.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.27M |
| 2 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$140K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$4K |
ORMP Hedge Fund Activity: Q3 2015 in Review
19 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2015, worth a combined $855K — down 55% from $1.91M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ORMP positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Tocqueville Asset Management, adding an estimated $126K. The largest seller was Sabby Management, cutting an estimated $1.27M.
- 19 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2015, up from 15 in Q2 2015.
- Funds reported $855K of Oramed Pharmaceuticals stock for Q3 2015, down 55% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q3 2015 and 1 closed out, a net change of +4 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2015 was Tocqueville Asset Management, an estimated $126K added.
- The largest Oramed Pharmaceuticals seller in Q3 2015 was Sabby Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q3 2015.